Pierre Bedossa
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 192 publications
Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.
Journal: Hepatology (Baltimore, Md.)
Published: December 17, 2025
Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.
Journal: Hepatology (Baltimore, Md.)
Published: December 17, 2025
Expert Delphi Consensus on Surrogate Endpoints for Treatment Assessment in Metabolic Dysfunction-Associated Steatohepatitis.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: October 29, 2025
An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.
Journal: Biomedicines
Published: September 26, 2025
Improving MASLD Risk Stratification in Young Adults with Cardiometabolic Risk Factors and Insulin Resistance Assessment.
Journal: Journal of the Endocrine Society
Published: September 16, 2025
Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial.
Journal: Journal of hepatology
Published: July 14, 2025
Fat-Corrected Non-Gaussian Diffusion MRI for Liver Fibrosis Assessment in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Journal: Journal of magnetic resonance imaging : JMRI
Published: July 01, 2025
AI portal tract detection and characterisation for a regional analysis of steatosis and inflammation in MASLD, MASH and AIH.
Journal: Journal of clinical pathology
Published: June 20, 2025
The Elucidating Pathways of Steatohepatitis (EPoS) staging system: A reproducible 7-tiered fibrosis scoring system in MASLD.
Journal: JHEP reports : innovation in hepatology
Published: May 25, 2025
Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Journal: Diagnostics (Basel, Switzerland)
Published: March 26, 2025
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
Journal: Lancet (London, England)
Published: March 24, 2025
Morphometric Quantification of Steatosis and Fibrosis in Metabolic Liver Disease Associated With Type 2 Diabetes.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: February 20, 2025
Last Updated: 09/26/2026